NO20076245L - Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner - Google Patents

Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner

Info

Publication number
NO20076245L
NO20076245L NO20076245A NO20076245A NO20076245L NO 20076245 L NO20076245 L NO 20076245L NO 20076245 A NO20076245 A NO 20076245A NO 20076245 A NO20076245 A NO 20076245A NO 20076245 L NO20076245 L NO 20076245L
Authority
NO
Norway
Prior art keywords
tfpi
bacterial infections
treat severe
risk
severe bacterial
Prior art date
Application number
NO20076245A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen F Hardy
Yumin Dai
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20076245L publication Critical patent/NO20076245L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20076245A 2005-05-06 2007-12-04 Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner NO20076245L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67846505P 2005-05-06 2005-05-06
PCT/US2006/017956 WO2006122139A2 (en) 2005-05-06 2006-05-08 Use of tfpi to treat severe bacterial infections

Publications (1)

Publication Number Publication Date
NO20076245L true NO20076245L (no) 2007-12-06

Family

ID=37103012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076245A NO20076245L (no) 2005-05-06 2007-12-04 Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner

Country Status (16)

Country Link
US (1) US20090214506A1 (pt)
EP (1) EP1877081A2 (pt)
JP (1) JP2008540460A (pt)
KR (1) KR20080017021A (pt)
CN (1) CN101400365A (pt)
AU (1) AU2006244053A1 (pt)
BR (1) BRPI0611049A2 (pt)
CA (1) CA2607293A1 (pt)
IL (1) IL187111A0 (pt)
MA (1) MA29489B1 (pt)
MX (1) MX2007013876A (pt)
NO (1) NO20076245L (pt)
RU (1) RU2007145202A (pt)
TN (1) TNSN07413A1 (pt)
WO (1) WO2006122139A2 (pt)
ZA (1) ZA200709520B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2015007880A1 (en) 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105777876B (zh) * 2016-05-26 2020-02-11 青岛农业大学 一种抗菌肽tc38及其应用
CN105777875B (zh) * 2016-05-26 2020-02-11 青岛农业大学 一种抗菌肽cstc24及其应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11572295B1 (en) * 2019-06-11 2023-02-07 Swamp Fox Innovations, LLC Compositions and methods for reduction of free chlorine and related odor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7674769B2 (en) * 2001-10-15 2010-03-09 Novartis Vaccines And Diagnostics, Inc. Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
EP1654283B1 (en) * 2003-08-13 2011-07-13 Novartis Vaccines and Diagnostics, Inc. Improved method of purifying tfpi and tfpi analogs

Also Published As

Publication number Publication date
CA2607293A1 (en) 2006-11-16
US20090214506A1 (en) 2009-08-27
WO2006122139A3 (en) 2007-04-26
JP2008540460A (ja) 2008-11-20
KR20080017021A (ko) 2008-02-25
IL187111A0 (en) 2008-02-09
EP1877081A2 (en) 2008-01-16
CN101400365A (zh) 2009-04-01
BRPI0611049A2 (pt) 2010-08-10
MX2007013876A (es) 2008-04-02
MA29489B1 (fr) 2008-05-02
AU2006244053A1 (en) 2006-11-16
RU2007145202A (ru) 2009-06-20
ZA200709520B (en) 2008-11-26
TNSN07413A1 (en) 2009-03-17
WO2006122139A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
WO2009021521A3 (en) Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression
WO2003032904A3 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
D’Avolio et al. Daptomycin pharmacokinetics and pharmacodynamics in septic and critically ill patients
MX2008013635A (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
MXPA05012392A (es) Tratamientos de ansiedad con ziprasidona.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
NO20064964L (no) Behandling av svekket respiratorisk funksjon
KR20120128644A (ko) 질환의 치료에 사용하기 위한 화합물
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
EA201590825A1 (ru) Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности
NO20064674L (no) Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor
RU2007112409A (ru) Одновременный прием тигициклина и дигоксина
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
NO20075898L (no) Behandling av samfunnsvervet lungebetennelse ved administrering av vevsfaktor pathway inhibitor (TFPI)
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2010045563A3 (en) Combination therapies for the treatment of obesity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application